Aura Biosciences

Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives of people with a wide range of cancers that are poorly managed today.

The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal.

Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical sector. The company focuses on Biotechnology and has secured $68.6B in funding across 180 round(s). With a team of 51-100 employees, Aura Biosciences is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Aura Biosciences, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.